ClinicalTrials.gg
Enrolling by invitationNCT07718906Updated Nov 13, 2026

Neuromodulation for Behavioral Changes in Neurological Disorders

An interventional study of Focused Ultrasound in Dementia, sponsored by West Virginia University. Enrolling by invitation at 1 site in United States. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by West Virginia University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now Enrolling by invitation1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.

Planned enrollment
753rd of 846
15 · median 93
Started
2026
with 64 others
No phase
562 of 1,051
118 open now
Primary completion
2027-12
later than 182 of 275 live
Registered
1,027th of 1,051
by date

Among the 1,051 studies in Dementia with a site in United States, this one is the 753rd largest by planned enrollment of the 846 interventional ones that give a count, is one of 65 that started in 2026, is one of 562 with no phase, reaches primary completion later than 182 of the 275 other live ones, and was the 1,027th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,051 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see if a focused ultrasound neuromodulation can be safely and effectively used to treat symptoms of emotional dysregulation such as agitation, irritability and anxiety

Read the detailed description

This open-label early feasibility study investigates low intensity focussed ultrasound (FUS), in participants with emotional dysregulation due to dementia. The primary objective is to test the safety and feasibility of FUS in this population.

03

Conditions studied

  • Dementia

Browse trials for

Keywords

  • Neuromodulation
  • Focused Ultrasound
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Age 45-80 years at time of enrollment.
  • Diagnosis of probable mild-stage neurodegenerative dementia, including Alzheimer's disease (AD), frontotemporal dementia (FTD, including behavioral variant and language variant), or dementia with Lewy bodies (LBD), based on established consensus clinical criteria.
  • Presence of (in treatment for or recommended for the symptoms) neuropsychiatric or behavioral symptoms including but not limited to anxiety, agitation, depression, irritability, apathy, or disinhibition
  • Able to undergo MRI scanning
  • Adequate auditory and visual abilities to complete study procedures as determined by the investigator.
  • Availability of a study partner (legally authorized representative, caregiver, or family member) who has regular contact with the participant and can provide collateral information and assist with assessments.
  • Ability to provide , or assent with legally authorized representative (LAR) consent in accordance with WVU IRB policy and applicable West Virginia law. .Currently under the care of a licensed physician, psychiatrist, or neurologist, and agrees to allow communication between investigators/study staff and healthcare providers for purposes of eligibility confirmation and safety monitoring.

EXCLUSION CRITERIA

  • Moderate to severe dementia (i.e., beyond mild stage).
  • Clinically significant MRI abnormality that may jeopardize participant safety, study conduct, or confound diagnostic assessments.
  • History of clinically significant neurological disorder other than the qualifying dementia diagnosis that could confound evaluation or increase risk.
  • Major psychiatric disorder that would interfere with participation or safety, including psychosis, active suicidal ideation, or severe mood/anxiety disorder requiring immediate intervention.
  • Elevated suicide risk with History of medically verified suicide attempt within the past year.
  • Use of medications that significantly lower the seizure threshold or interfere with neuromodulation safety, as determined by the study physician.
  • Use of drugs or participation in another interventional clinical trial within 30 days prior to screening.
  • Any condition that, in the opinion of the investigator, would interfere with study participation, safety, or interpretation of results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Treatment

    FUS Neuromodulation

    Device: Focused Ultrasound

Interventions

  • DeviceFocused Ultrasound

    Subjects will undergo a single focused ultrasound Neuromodulation of the target brain region

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events

    All adverse events that are related to FUS treatment will be assessed

    Time frame: Week 12 compared to baseline

Secondary outcomes

  1. Change in behavioral symptoms

    Change in behavioral symptoms as assessed by NPI

    Time frame: Week 12 compared to baseline

  2. Changes in Anxiety symptoms

    Changes in Anxiety symptoms as measured by GAD-7

    Time frame: Week 12 compared to baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 17 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 22, 2026
StartActual
Jul 25, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • West Virginia University: Rockefeller Neuroscience Institute · Morgantown, United States
Show 1 removed
  • WVU Rockefeller Neuroscience Institute · Morgantown, United States
Nov 13, 2026
Contact
No study contact listed any more: removed m•••@hsc.wvu.edu · •••8182; removed j•••@hsc.wvu.edu · •••5886
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Enrolling by invitation
    1 site added, 1 site removed
    Show site
    • West Virginia University: Rockefeller Neuroscience Institute · Morgantown, United States
    Show 1 removed
    • WVU Rockefeller Neuroscience Institute · Morgantown, United States
    Contact No study contact listed any more: removed m•••@hsc.wvu.edu · •••8182; removed j•••@hsc.wvu.edu · •••5886
    + 2 other changes: date precision and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07718906
Responsible party
Ali Rezai (Executive Chair and Director, West Virginia University) — Principal investigator
First posted
Jul 22, 2026
Start date
Jul 25, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Ali Rezai
principal investigator · WVU Rockefeller Neuroscience Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion